NRx Pharmaceuticals, Inc. Announces Pricing and Closing of Public Offering of Common Stock

Key Developments

• Date of Events: Pricing announced June 3, 2026; Closing announced June 4, 2026.
• Offering Size: 5,714,286 shares of common stock offered, with an option for underwriters to purchase up to an additional 857,142 shares (the “Optional Shares”), potentially increasing the offering size.
• Underwriter: BTIG, LLC acted as the representative for the underwriters in the transaction.
• Exchange: Shares are listed on The Nasdaq Stock Market LLC.
• Lock-Up Agreements: The company, its directors, and executive officers agreed not to sell or transfer any shares for 60 days without underwriter consent, subject to customary exceptions.
• Use of Proceeds: Net proceeds to be used as specified under “Use of Proceeds” in the prospectus, with details available in the official filings.
• Legal Compliance: The offering was made pursuant to an effective shelf Registration Statement on Form S-3, with all required SEC filings completed and no stop orders issued.

Details of the Underwriting Agreement

On June 3, 2026, NRx Pharmaceuticals, Inc. (“the Company”) entered into a definitive Underwriting Agreement with BTIG, LLC, as representative of the underwriters. The agreement covers the sale of 5,714,286 shares of common stock, with an additional 857,142 shares available through an over-allotment option, collectively referred to as the “Offered Shares.”

The Underwriters have committed to purchase the shares at a set price and resell them to the public. The company made several warranties and representations regarding its compliance with securities laws, the accuracy of its filings, and the absence of material adverse changes or undisclosed liabilities. The agreement also includes detailed indemnification and contribution provisions to protect the underwriters and the company from liability related to the offering.

Shareholder and Price-Sensitive Information

• Lock-Up Period: The company, its directors, and executive officers are restricted from selling shares for 60 days post-agreement, which may help stabilize the share price in the short term by reducing the risk of insider selling.
• No Registration Rights: There are no outstanding registration rights or similar arrangements that would allow other securities to be registered and sold as part of this offering, reducing the risk of unexpected dilutive events.
• Financial Health and Disclosure: The company has certified that since its last filings, there have been no material adverse changes, undisclosed liabilities, or significant events that would negatively impact the business, financial condition, or prospects.
• Use of Proceeds: The company has committed to use the net proceeds from the offering as described in the prospectus, which typically supports ongoing operations, research & development, and other strategic initiatives.
• Legal and Regulatory Compliance: The offering was conducted in full compliance with SEC regulations, and both the company’s internal and disclosure controls have been described as effective.
• Forward-Looking Statements: The company has provided forward-looking statements regarding its future plans and strategies, with appropriate disclaimers about risks and uncertainties.

Risk Factors and Market Impact

• The offering increases the number of outstanding shares, which may dilute existing shareholders’ holdings.
• The company’s forward-looking statements caution about risks related to market conditions, regulatory milestones, and other factors that could materially affect actual results.
• The absence of any material adverse events or undisclosed liabilities is a positive sign, but the company encourages investors to review all risk factors in its most recent filings with the SEC.

Conclusion

The successful pricing and closing of this public offering is a significant event for NRx Pharmaceuticals, Inc., providing additional capital for the company’s operations and strategic initiatives. The lock-up arrangements, absence of registration rights, and confirmation of no adverse changes are all important factors that may impact investor sentiment and the company’s share price in the near term.

Investors should closely monitor the company’s SEC filings and future announcements for further developments, especially regarding the use of proceeds and any material events that could affect the company’s outlook.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. Investors should review all official filings and consult their financial advisors before making any investment decisions.